Teacher Retirement System of Texas Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Teacher Retirement System of Texas increased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 229.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,775 shares of the biotechnology company's stock after buying an additional 6,805 shares during the quarter. Teacher Retirement System of Texas' holdings in Repligen were worth $1,407,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in RGEN. Xponance Inc. raised its position in shares of Repligen by 7.1% during the fourth quarter. Xponance Inc. now owns 6,939 shares of the biotechnology company's stock worth $999,000 after purchasing an additional 459 shares during the period. Signaturefd LLC raised its holdings in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the last quarter. Polen Capital Management LLC lifted its stake in shares of Repligen by 14.6% in the fourth quarter. Polen Capital Management LLC now owns 40,556 shares of the biotechnology company's stock valued at $5,838,000 after buying an additional 5,173 shares in the last quarter. CBIZ Investment Advisory Services LLC acquired a new position in shares of Repligen during the fourth quarter valued at about $58,000. Finally, Natixis Advisors LLC increased its position in shares of Repligen by 31.8% during the fourth quarter. Natixis Advisors LLC now owns 44,317 shares of the biotechnology company's stock worth $6,379,000 after acquiring an additional 10,692 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RGEN. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group lifted their target price on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Royal Bank of Canada increased their price target on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. Finally, JPMorgan Chase & Co. increased their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of "Hold" and a consensus target price of $178.64.

Repligen Stock Performance

NASDAQ RGEN traded up $2.42 during trading hours on Wednesday, reaching $130.92. 863,650 shares of the company were exchanged, compared to its average volume of 678,192. The stock has a market capitalization of $7.35 billion, a P/E ratio of -256.71, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $182.52. The business's 50 day simple moving average is $152.03 and its 200-day simple moving average is $147.88.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. On average, equities research analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.